Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Intracranial embolism
- Focus Therapeutic Use
- Acronyms ODIn-AF
- 16 Aug 2019 Status changed from recruiting to suspended.
- 31 Aug 2018 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 31 Aug 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2020.